With the sale of restructuring collagen products, it has entered a year of hundreds of millions of p

Picture Source: Jinbo Bio Officer Micro Screenshot

is not satisfied with the restructuring collagen market, and Jinsbo biology also wants to make medicine.

On June 7, a reporter from the Beijing Commercial Daily was informed that the application for the listing of the Beijing Stock Exchange of Jinsbo was accepted. According to the prospectus, Jinsbo Bio was listed on the market to raise 602 million yuan, of which 100 million yuan was invested in the research and development project of the broad -spectrum anti -coronary virus.

The listing application was accepted

Following the submission of the Bitza Bio that moved to the Bei Stock Exchange and the Giant Biology to the Hong Kong Stock Exchange, on June 7, a reporter from the Beijing Commercial Daily learned that Jinsbo Biological The Beijing Stock Exchange's listing materials have been accepted, and the sponsor is CITIC Securities.

For Ferrishalin data, according to the retail sales, from 2022 to 2027, the market size of my country's reorganized collagen products will increase from 18.5 billion yuan to 108.3 billion yuan from 42.4%to 108.3 billion yuan. Yuan.

Reorganized collagen products constituted half of the biological revenue of brocade biological revenue. According to the prospectus, the main products of Jinsbo include restructuring collagen products and anti -HPV biomromin products. Among them, the main products in the field of restructuring collagen products include reorganized type III human -source collagen frozen -dry fiber, wound and mucosal repair dressing, functional skin care products, etc. From 2019 to 2021, the revenue of Jinsbo Bio-reorganized collagen products was 62.5588 million yuan, 101 million yuan, and 163 million yuan, respectively, accounting for 44.21%, 62.96%, and 69.81%of the main business revenue, respectively.

Most of the fundraising of Jinsbo Bio will also be invested in reorganized collagen projects. The prospectus shows that the company's total investment in raised funds was 602 million yuan, of which 232 million yuan was invested to reorganized humanized collagen new materials and injection product research and development projects.

It is worth mentioning that before turning to the North Stock Exchange, Jinsuo Bio once sprinted to the Shanghai Stock Exchange Science and Technology Board. In June 2020, Jinsuo Bio began to accept the queue on the IPO of the Science and Technology Board, and then actively withdrew the IPO application for \"strategic adjustment\". The Creator creature at the same track was expected to meet the requirements of \"operating income in the past year to reach 300 million yuan\" due to its estimated performance in 2021. The science and technology board registration was terminated. Submit the listing of listing counseling, and the counseling agency is CITIC Securities.

Zhang Wenbo, senior partner of Beijing Jundu Shanghai Law Firm, Director of Life Science and Health Medical Law, said in an interview with the Beijing Business Daily reporter that the competitive threshold for restructuring the collagen industry is low, the listing of its own brand premium aura effect. The listing of Jinsbo Biological will open up the financing channels and various financing tools for circulating equity, so that it can further \"horses and circles\" in the industry.

New crown medicine for cross -border layout

Different from Giant ShengFocusing on the main business, the fundraising investment, expansion of the production capacity related to product portfolio and biological activity ingredients, enhance omni -channel sales and distribution networks, etc., Jinbo Biological fundraising will invest 156 million yuan for a wide range of spectrum spectrum. R \u0026 D project of coronary virus new drugs.

The prospectus stated that the EK1 atomizer EK1 at the broad -spectrum antivirus of the Coronary Coronary Virus developed by Jinsbo was obtained by the \"Pharmaceutical Clinical Test Approval Notice\" issued by the State Drug Administration in September 2021. At present, the drug has entered the phase I clinical stage. Basic research results show that EK1 atomizer has a broad -spectrum for the new coronary virus, and has good antiviral activity for the six coronary viruses and three kinds of infected bats including new coronary viruses and three types of infected bats.

However, the new drug has a long period of research and development and a large investment in funds, and Jinsbo Bio still faces greater uncertainty. Public data shows that the average process of developing a new drug and pushing to the market will cost an average of $ 2.6 billion. From the perspective of the prospectus, the R \u0026 D investment of Jinsbo is less than sales revenue. From 2019-2021, the sales costs of Jinsbo Bio were 43.205 million yuan, 37.5351 million yuan, and 55.967 million yuan, respectively, accounting for 27.59% of operating income, respectively 27.59%, respectively. , 23.27%and 23.98%, while the proportion of R \u0026 D investment in the past three years accounted for less than 20%.

Jinsbo Bio also appeared in the prospectus that the total investment of the newly spent anti -coronary virus new drug research and development project is 156 million yuan. Before the fundraising funds are in place, the company must be funded by the company. Fund pressure. In addition, the clinical trials and approval cycles of innovative drugs are long, and there are certain uncertainties. If the company's new product research and development progress has not been expected, technical difficulties fail to break through or new products cannot be obtained by market recognition, there is a failure of project research and development failure, then there is a failure of project research and development failure. Risk, which has a adverse effect on the company's production and operation.

It is understood that the development of a new drug to the market is a complex and consumed process, involving high cost, high risk and strict compliance requirements. Zhang Wenbo believes that the new crown drug may have room for imagination and it is easier to integrate funds.

Reporter 丨 Yao Qian

Photo source 丨 Visual China, Jinsbo Biosi Weimi

- END -